Bifunctional PROTAC Compounds for Targeted FLT3 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with overexpression or aggregation of FMS-like tyrosine kinase 3 (FLT3) are hindered by non-specific effects and the inability to specifically target and modulate FLT3, limiting the development of effective therapies.
Innovation Solution
Development of bifunctional compounds, known as proteolysis targeting chimeric (PROTAC) compounds, which recruit endogenous proteins to an E3 ubiquitin ligase for degradation, specifically targeting FLT3 by combining a protein/polypeptide targeting moiety with an E3 ubiquitin ligase binding moiety, such as Von Hippel-Lindau, cereblon, or mouse double minute 2 homolog, to facilitate targeted ubiquitination and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for FLT3-associated diseases are used, then disease treatment is attempted, but non-specific effects occur and the inability to specifically target and modulate FLT3 limits effectiveness
Solution Approach 1:
The compound is divided into two distinct functional moieties: a first moiety that specifically binds to FLT3 and a second moiety that recruits the E3 ubiquitin ligase. This segmentation allows each part to perform its specific function independently, ensuring high specificity for FLT3 while avoiding non-specific effects on other proteins.
Solution Approach 2:
The bifunctional compound acts as an intermediary that bridges FLT3 and the E3 ubiquitin ligase. By containing both binding sites within a single molecule, it mediates the recruitment process and ensures that only FLT3 is targeted for degradation, eliminating the non-specific effects associated with general proteasome inhibitors.
2Reliability
If bifunctional PROTAC compounds are developed to specifically target FLT3, then specific modulation of FLT3 levels is achieved, but the complexity of designing and synthesizing such compounds increases
Solution Approach 1:
The complex bifunctional compound is designed by segmenting it into two well-defined functional moieties connected by a linker. This modular approach simplifies the design process by allowing independent optimization of each binding site while maintaining overall compound functionality.
Solution Approach 2:
The bifunctional compound structure serves multiple functions simultaneously: the first moiety provides specific FLT3 binding, the linker provides structural flexibility and positioning, and the second moiety recruits the E3 ubiquitin ligase. This multi-functionality within a single molecular framework achieves complex therapeutic goals without requiring multiple separate compounds.
3Ease of manufacture
If traditional small molecule drugs are used, then they bind to enzymes or receptors in tight pockets, but they cannot effectively target protein-protein interactions due to large contact surfaces and shallow grooves
Solution Approach 1:
The bifunctional compound serves as an intermediary that overcomes the limitations of targeting shallow protein-protein interaction interfaces. By providing two separate binding sites within one molecule, it creates effective binding at both the FLT3 interface and the E3 ligase interface, making previously undruggable protein-protein interactions targetable.
Solution Approach 2:
The invention merges two separate binding functions into a single bifunctional compound. This combination allows the compound to simultaneously engage both FLT3 and the E3 ubiquitin ligase, effectively targeting the protein-protein interaction between them that would be inaccessible to traditional single-function small molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enable the broad pharmacological activity of degrading or inhibiting targeted polypeptides, effectively treating conditions like acute myeloid leukemia by specifically modulating FLT3 levels, offering a promising approach for cancer therapy.
Implementation Method 1
bifunctional compounds, known as proteolysis targeting chimeric (PROTAC) compounds, which recruit endogenous proteins to an E3 ubiquitin ligase for degradation, specifically targeting FLT3 by combining a protein/polypeptide targeting moiety with an E3 ubiquitin ligase binding moiety, such as Von Hippel-Lindau, cereblon, or mouse double minute 2 homolog, to facilitate targeted ubiquitination and degradation
Data Source
AI summary
The present disclosure relates to bifunctional compounds, which find utility as modulators of FLT3 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein FLT3, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of the target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.